Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.6800 (0%) ($8.0500 - $9.1000) on Wed. Sep. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.12% (three month average) | RSI | 25 | Latest Price | $8.6800(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.6% a day on average for past five trading days. | Weekly Trend | HTBX declines -12.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(35%) XBI(34%) ARKK(32%) BLOK(30%) IBB(30%) | Factors Impacting HTBX price | HTBX will decline at least -5.56% in a week (0% probabilities). VXX(-20%) VIXM(-17%) UUP(-14%) IGOV(-11%) UNG(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -5.56% (StdDev 11.12%) | Hourly BBV | -0.3 () | Intraday Trend | -3.1% | | | |
|
1 - 5 Day Possible Target | $-28.15(-424.31%) | Resistance Level | $10.74 | 5 Day Moving Average | $8.85(-1.92%) | 10 Day Moving Average | $9.06(-4.19%) | 20 Day Moving Average | $10.74(-19.18%) | To recent high | -65.7% | To recent low | 67.5% | Market Cap | $955m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |